Aleniglipron (GSBR-1290)

May 07, 2026 — Structure Therapeutics Inc. (NASDAQ: GPCR) reported Q1 2026 financial results and provided clinical/program updates for its oral metabolic pipeline. The company highlighted Phase 2 ACCESS II topline data for aleniglipron (oral small-molecule GLP‑1 receptor agonist) showing placebo-adjusted mean weight loss at 44 weeks of 16.3% (39 lbs; p<0.0001) at 180 mg and 16.0% (37 lbs; p<0.0001) at 240 mg; in the ACCESS open-label extension, weight loss reached 16.2% (40.5 lbs) at 56 weeks (120 mg). No weight-loss plateau was observed. Structure said it received positive FDA end-of-Phase 2 feedback, with Phase 3 initiation for chronic weight management planned for Q3 2026 (starting titration dose 2.5 mg; multiple doses to be evaluated). Additional readouts are expected: ACCESS OLE (Q3 2026) and body composition/T2DM-overweight and SWITCH switching study data (Q4 2026). The company also noted Phase 1 SAD data for oral amylin agonist ACCG‑2671 expected in 2H 2026 (MAD to start Q3 2026) and Phase 1 start for ACCG‑3535 in Q4 2026, plus multiple ADA June 2026 presentations. Financially, cash/cash equivalents/short-term investments were $1.5B (March 31, 2026), including a $100M upfront patent license fee, projected to fund operations through end of 2028; Q1 R&D was $66.5M, G&A $22.9M, and net loss $76.0M.